ORIC Pharmaceuticals
NASDAQ: ORICSouth San Francisco, US · Founded 2014 · Delaware corporation · 138 employees on LinkedIn · 6 known investors
Find your way into ORIC Pharmaceuticals
515 people in our graph share verified history with the ORIC Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.
Paul Bragielunlockedknows Kevin Brodbeck · together at University of Illinois Urbana-Champaign (overlapped)
%20(1).png)
knows the team · via Harvard Medical School
knows the team · via Salk Institute for Biological Studies
×3knows the team · via Harvard T.H. Chan School of Public Health
×4knows the team · via ARCH Venture Partners
knows the team · via Vividion Therapeutics
ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance. Its pipeline includes rinzimetostat (ORIC-944) in Phase 1b for prostate cancer and enozertinib (ORIC-114) in Phase 1b for non-small cell lung cancer with EGFR mutations.
Founders & leadership
ORIC Pharmaceuticals was founded in 2014 by Richard Heyman, Charles Sawyers, and Scott Lowe.
RH
CS
Charles SawyersFounder, Scientific Advisory BoardScience Partner at Nextech Invest
SL
Scott LoweFounder, Scientific Advisory Board
DP
Dominic PiscitelliinChief Financial Officer
PM
Pratik MultaniinChief Medical OfficerPratik Multani is a medical oncologist with experience across the drug development lifecycle, including regulatory submissions, clinical trial design and execution, and FDA interactions. He has led cross-functional teams and brings expertise in strategic planning, trial execution, and stakeholder communication in oncology.
JC
Jacob ChackoinPresident, Chief Executive Officer and Board Member
KB
Kevin BrodbeckinChief Technical OfficerKevin Brodbeck holds a Ph.D. in chemical engineering from UC Berkeley and the University of Illinois Urbana-Champaign. He spent nine years at Nektar Therapeutics leading CMC development across oncology, immunotherapy, and other therapeutic areas, and previously held roles in product development at ALZA/Johnson & Johnson (where he led development of the Viadur leuprolide implant and the Injectable Depot platform) and as head of biopharmaceutical formulation at Powderject.
LF
Lori FriedmaninChief Scientific Officer
MP
Matthew PanuwatChief Business Officer
CV
Christian V. KuhleninGeneral Counsel
Board
SL
LK
Lori KunkelBoard director
Investors · 6
Reported raises · per SEC filings
Form D private placements$335M disclosed across 3 rounds · 2023–2025
▶$125MraisedJun 2025 · 15 investors · BiotechnologyRule 506(b)
▶$125MraisedJun 2025 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steve L. HoerterDirector
- Lori KunkelDirector
- Jacob M. ChackoExecutive Officer, Director
- Richard HeymanDirector
- Dominic PiscitelliExecutive Officer
- Angie YouDirector
- Pratik MultaniExecutive Officer
- Mardi C. DierDirector
- Offering amount
- $125M
- Amount sold
- $125M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$125MraisedJan 2024 · 10 investors · BiotechnologyRule 506(b)
▶$125MraisedJan 2024 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Angie YouDirector
- Lori KunkelDirector
- Steve L. HoerterDirector
- Dominic PiscitelliExecutive Officer
- Jacob M. ChackoExecutive Officer, Director
- Richard HeymanDirector
- Mardi DierDirector
- Pratik MultaniExecutive Officer
- Offering amount
- $125M
- Amount sold
- $125M
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$85MraisedJul 2023 · 12 investors · BiotechnologyRule 506(b)
▶$85MraisedJul 2023 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Angie YouDirector
- Richard HeymanDirector
- Steve L. HoerterDirector
- Jacob M. ChackoExecutive Officer, Director
- Mardi DierDirector
- Lori KunkelDirector
- Dominic PiscitelliExecutive Officer
- Pratik MultaniExecutive Officer
- Offering amount
- $85M
- Amount sold
- $85M
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$818.6Mvaluation at IPONov 2020 · $23.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
2 people who came through ORIC Pharmaceuticals went on to found or lead other companies.
Competitors · 2
by search overlap
Seeking Alpha28 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Robinhood22 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with ORIC Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
ORIC Pharmaceuticals Grants 125,400 Stock Options | ORIC Stock Newsstocktitan.net · Aug 2026
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | The Manila Timesmanilatimes.net · Aug 2026Frequently asked questions
- What does ORIC Pharmaceuticals do?
- ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance. Its pipeline includes rinzimetostat (ORIC-944) in Phase 1b for prostate cancer and enozertinib (ORIC-114) in Phase 1b for non-small cell lung cancer with EGFR mutations.
- Who founded ORIC Pharmaceuticals?
- ORIC Pharmaceuticals was founded by Richard Heyman, Charles Sawyers, Scott Lowe in 2014.
- Who are ORIC Pharmaceuticals's investors?
- ORIC Pharmaceuticals's investors include EcoR1 Capital, New Enterprise Associates (NEA), Nextech Invest, Taiho Ventures, LLC, The Column Group, OrbiMed.
- How much funding has ORIC Pharmaceuticals raised?
- ORIC Pharmaceuticals has disclosed $335M raised across 3 rounds.
- Where is ORIC Pharmaceuticals headquartered?
- ORIC Pharmaceuticals is headquartered in South San Francisco, US.